Product Development - The lead product candidate, ML-007C-MA, is being developed for schizophrenia and Alzheimer's disease psychosis, with a target enrollment of 300 participants expected by April 2026 for the Phase 2 trial ZEPHYR, and topline results anticipated in Q3 2026[20]. - ML-007C-MA has been evaluated in four Phase 1 trials with a total of 270 healthy participants and over 1,500 doses administered, demonstrating potential for well-tolerated treatment with convenient dosing[20]. - The company is also conducting a Phase 2 trial, IRIS, for ML-004, targeting social communication deficits in autism spectrum disorder, with topline results expected in Q3 2026[26]. - ML-009, a GPR52 PAM program for hyperactivity and impulsivity, is expected to complete IND-enabling studies in 2027[27]. - ML-055, a next-generation M1/M4 muscarinic agonist, aims to advance to IND-enabling studies in 2026[27]. - The pipeline includes diverse mechanisms and neural circuits to address various CNS disorders, retaining global development and commercial rights to all programs[29]. - The company utilizes a platform combining optogenetics, single-cell transcriptomics, and STARmap to identify druggable targets within disease-related neural circuits[32]. Unmet Medical Need - Approximately 40% of the 7 million people in the U.S. living with Alzheimer's disease experience symptoms of psychosis, indicating a significant unmet need for effective treatments[22]. - Approximately 30% of patients do not respond to dopaminergic antipsychotics, and 30% to 60% have only a partial response, highlighting a significant unmet medical need[38]. - There are currently no FDA-approved therapies for Alzheimer's disease psychosis, and off-label antipsychotics carry increased mortality risks in elderly patients[40]. - The current pipeline addresses significant disease burdens, with millions affected by CNS conditions, highlighting the need for innovative therapeutic options[28]. - There are currently no FDA-approved therapies for the core symptoms of ASD, highlighting the significant need for effective treatments[129][130]. Clinical Trials and Results - The Phase 2 ZEPHYR Study for schizophrenia aims to enroll approximately 300 participants, with a primary efficacy endpoint of change in total PANSS score from baseline to week 5[114][115][117]. - The ongoing Phase 2 VISTA trial employs a 1-week titration to reach the target maintenance dose for Alzheimer's disease patients[80]. - In the ongoing Phase 2 trials, ML-007C-MA will be dosed proximal to a meal, as tolerability was improved in fed conditions compared to fasted conditions[81]. - The ongoing clinical trials for ML-007C-MA include a double-blind, placebo-controlled design, with participants randomized to receive either placebo or ML-007C-MA 210/3 mg BID[121][115]. - The ongoing Phase 2 IRIS trial has enrolled approximately 160 participants with ASD to evaluate the efficacy of ML-004, with primary endpoint results expected after 12 weeks of maintenance dosing[143]. Safety and Efficacy - The safety profile of ML-007C-MA supported advancing doses up to 210/3 mg BID and 330/6 mg QD for the Phase 2 ZEPHYR trial in schizophrenia[75]. - Most treatment-emergent adverse events (TEAEs) were mild and transient, with no serious or severe adverse events reported during the trials[77]. - At the target doses for the ongoing Phase 2 ZEPHYR trial, 67% of participants receiving 330/6 mg experienced any TEAE, compared to 25% in the placebo group[98]. - ML-007 significantly improved spatial memory in a mouse model of Alzheimer's disease, while xanomeline did not show similar effects[85]. - The predicted CSF exposures for target doses of 210/3 mg BID and 330/6 mg QD were at or above the target range for most of the dosing period[76]. Regulatory and Compliance - The FDA granted Fast Track designation to ML-007C-MA in December 2025 for treating hallucinations and delusions associated with Alzheimer's disease psychosis[20]. - The FDA review process for new drugs typically takes about 10 months from the date of filing for a standard NDA, with a total review time of approximately 12 months[187]. - The FDA may issue an approval letter or a Complete Response Letter (CRL) after evaluating a New Drug Application (NDA) and conducting inspections of manufacturing facilities[189]. - A CRL indicates that the application will not be approved in its current form and may require additional clinical data or trials[189]. - The Fast Track designation program expedites the development and review of product candidates intended to treat serious diseases and address unmet medical needs[193]. Intellectual Property and Competition - As of December 31, 2025, the company holds approximately 86 issued patents and pending patent applications related to its product candidates and proprietary technology[151]. - The patent estate includes five issued foreign patents for ML-004, with pending applications expected to expire in 2040 and 2042, depending on the application[154]. - The company relies on trademarks, trade secrets, and know-how to maintain its competitive position in neuropsychiatric medicine, with seven trademark registrations as of February 25, 2026[160]. - The biotechnology and pharmaceutical industries are characterized by intense competition, with potential competitors having greater financial resources and established market presence[166][167]. - The company is developing ML-007C-MA for the treatment of schizophrenia, facing competition from existing antipsychotic treatments and other companies developing similar products[169][170].

Core Viewpoint - MapLight Therapeutics, Inc. is positioned to achieve significant development milestones in 2026, focusing on clinical trials for central nervous system disorders and expanding its drug pipeline [2]. Business Update and Upcoming Milestones - The company expects to reach target enrollment of 300 participants in the Phase 2 ZEPHYR trial for schizophrenia by April 2026, with topline results anticipated in the third quarter of 2026 [5]. - The Phase 2 IRIS trial for autism spectrum disorder has completed enrollment, with topline results also expected in the third quarter of 2026 [5]. - The FDA has granted Fast Track designation for ML-007C-MA for Alzheimer's disease psychosis, with topline results from the Phase 2 VISTA trial expected in the second half of 2027 [5]. - The company is advancing its next-generation M1/M4 muscarinic agonist program, ML-055, with candidate nomination expected in 2026 [5]. Financial Results - As of December 31, 2025, the company reported cash, cash equivalents, and investments totaling $453.1 million, sufficient to fund operations through 2027 [4][7]. - Research and development (R&D) expenses for Q4 2025 were $64.6 million, up from $20.7 million in Q4 2024, with full-year R&D expenses reaching $138.3 million compared to $68.5 million in 2024 [12]. - General and administrative (G&A) expenses for Q4 2025 were $18.8 million, compared to $2.1 million in the prior year, with full-year G&A expenses totaling $30.7 million versus $14.4 million in 2024 [12]. - The net loss for Q4 2025 was $79.5 million, compared to $21.2 million in Q4 2024, with a full-year net loss of $161.2 million compared to $77.6 million in 2024 [12].

Core Viewpoint - MapLight Therapeutics, Inc. is actively engaging with investors through participation in multiple upcoming conferences, showcasing its commitment to transparency and investor relations [1]. Group 1: Upcoming Events - The company will participate in the Jefferies 2026 Biotech on the Beach Summit on March 10th, hosting 1x1 meetings [1]. - On March 11th, MapLight will present and host 1x1 meetings at the Leerink 2026 Global Healthcare Conference [1]. - The Stifel 2026 Virtual CNS Forum will take place on March 18th, where the company will also present and host 1x1 meetings [1]. Group 2: Company Overview - MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on addressing central nervous system disorders [2]. - The company was founded by leaders in psychiatry and neuroscience to develop circuit-specific pharmacotherapies [2]. - Its discovery platform aims to identify neural circuits linked to diseases for targeted therapeutic modulation [2].

Financial Position - As of December 31, 2025, MapLight Therapeutics, Inc. reported cash and cash equivalents of approximately $450 million[6] - The preliminary cash and cash equivalents figure is subject to change upon completion of the financial closing procedures and the preparation of audited financial statements[7] - The financial information provided is preliminary and has not been audited, indicating potential variations from actual financial results[7] - The corporate presentation includes selected preliminary financial information for the fiscal year ended December 31, 2025[6] Clinical Trials - The company announced that topline results from its ongoing Phase 2 ZEPHYR and IRIS clinical trials are now expected in the third quarter of 2026[9] - The press release regarding the update on clinical trial results was issued on January 9, 2026[9] Corporate Governance - MapLight Therapeutics is classified as an emerging growth company under the Securities Act[5] - The company has not elected to use the extended transition period for complying with new or revised financial accounting standards[5] - The independent registered public accounting firm has not conducted an audit or review of the preliminary estimate provided[7] Investor Relations - The company updated its corporate presentation for investor meetings, which is available on its website[10]

Core Insights - MapLight Therapeutics, Inc. has updated the expected timing for topline results from its Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule [1] Group 1: ZEPHYR Trial - The Phase 2 ZEPHYR trial is evaluating ML-007C-MA for treating schizophrenia and is expected to report topline results in Q3 2026 [2] - The ZEPHYR study is a randomized, double-blind, placebo-controlled trial enrolling approximately 300 hospitalized adult participants experiencing acute exacerbation of psychosis [2][3] - The accelerated enrollment pace in the ZEPHYR trial has allowed the company to narrow its timing guidance to Q3 2026, reflecting disciplined execution and commitment to quality [3] Group 2: IRIS Trial - The Phase 2 IRIS trial for ML-004 in autism spectrum disorder has completed enrollment, with topline results also expected in Q3 2026 [3] - The IRIS study is a double-blind, placebo-controlled trial that randomized around 160 adult and adolescent participants [3] Group 3: Company Overview - MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with central nervous system disorders [4] - The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies [4] - MapLight's discovery platform aims to identify neural circuits linked to diseases and target them for therapeutic modulation [4]

Core Viewpoint - MapLight Therapeutics has received Fast Track designation from the FDA for its investigational drug ML-007C-MA, aimed at treating hallucinations and delusions associated with Alzheimer's disease psychosis, highlighting the significant unmet medical need in this area [1][2][3] Group 1: Drug Development and Clinical Trials - ML-007C-MA is an oral, extended-release, fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, designed to mitigate peripheral cholinergic side effects while activating central nervous system receptors [4] - The drug has shown a favorable safety and tolerability profile in a Phase 1 clinical trial, with ongoing enrollment in a Phase 2 randomized, double-blind, placebo-controlled trial expected to include 300 participants, with topline results anticipated in the second half of 2027 [3][4] Group 2: Alzheimer's Disease Psychosis (ADP) - Alzheimer's disease psychosis is a common neuropsychiatric complication affecting approximately 40% of individuals with Alzheimer's disease, leading to poorer outcomes such as faster cognitive decline and increased mortality [5] - The lack of currently approved treatment options for ADP underscores the importance of developing new therapies like ML-007C-MA [3][5] Group 3: Company Overview - MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on addressing central nervous system disorders, founded by leaders in psychiatry and neuroscience research [6] - The company's discovery platform aims to identify and target neural circuits linked to diseases, potentially filling a significant gap in available pharmacotherapies [6]

Core Insights - The U.S. FDA has granted Fast Track designation to MapLight Therapeutics' investigational drug ML-007C-MA for treating hallucinations and delusions associated with Alzheimer's disease psychosis [1][2][3] Group 1: Drug Development and Clinical Trials - Fast Track designation aims to expedite the development and review of therapies for serious conditions with unmet medical needs, allowing for more frequent FDA interactions and potential accelerated approval [2] - ML-007C-MA has shown a favorable safety and tolerability profile in a Phase 1 clinical trial with healthy elderly participants, and the ongoing Phase 2 VISTA study aims to enroll 300 participants [3][4] - Topline results from the Phase 2 VISTA study are expected in the second half of 2027 [3] Group 2: Drug Mechanism and Potential - ML-007C-MA is an oral, extended-release, fixed-dose combination designed to activate M1 and M4 muscarinic receptors in the central nervous system, potentially mitigating peripheral cholinergic side effects [4] - The drug aims to provide a well-tolerated treatment option with convenient dosing while achieving significant central nervous system exposure [4] Group 3: Alzheimer's Disease Psychosis (ADP) - ADP is a common neuropsychiatric complication of Alzheimer's disease, affecting approximately 40% of individuals at some point, leading to poorer outcomes such as faster cognitive decline and increased mortality [5] - The lack of currently approved treatment options highlights the significant unmet need for effective therapies in this area [3][5] Group 4: Company Overview - MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on addressing central nervous system disorders, founded by leaders in psychiatry and neuroscience research [6] - The company's discovery platform aims to identify and target neural circuits linked to diseases, filling a gap in available pharmacotherapies [6]

Core Insights - SandboxAQ and MapLight Therapeutics have entered a strategic collaboration to develop therapies targeting a novel G protein-coupled receptor (GPCR) for central nervous system (CNS) disorders [1][2] Financial Terms - SandboxAQ received an upfront payment and is eligible for additional milestone payments totaling up to $200 million, covering preclinical, development, regulatory, and commercial stages [2] Research Collaboration - The collaboration involves joint preclinical research, with MapLight holding exclusive rights for clinical development and commercialization of the compounds [2] - SandboxAQ will utilize its AI platform to enhance the discovery and development of therapies, focusing on receptor structure-functional activity and ligand-receptor interactions [3][4] Technological Advancements - SandboxAQ's AQBioSim platform allows for precise simulation and prediction of molecular interactions with GPCRs, facilitating a systematic exploration of chemical space [4] - The collaboration aims to accelerate the generation and optimization of potential drug candidates through rapid Design-Make-Test-Analyze (DMTA) cycles [3][4] Company Backgrounds - SandboxAQ is a B2B company that integrates AI and quantum techniques, emerging from Alphabet Inc. and focusing on various sectors including life sciences [5] - MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to addressing CNS disorders through circuit-specific pharmacotherapies, leveraging expertise in psychiatry and neuroscience [6]

Core Insights - SandboxAQ and MapLight Therapeutics have entered a strategic collaboration to develop therapies targeting a novel G protein-coupled receptor (GPCR) for central nervous system (CNS) disorders [1][2] Financial Terms - SandboxAQ received an upfront payment and is eligible for additional milestone payments totaling up to $200 million, which includes preclinical, development, regulatory, and commercial milestones [2] Research Collaboration - The collaboration will involve joint preclinical research activities, with MapLight holding exclusive rights for clinical development and commercialization of the compounds [2] - SandboxAQ will utilize large-scale AI models and high-fidelity molecular simulations to explore receptor structure-functional activity and optimize drug properties [3][4] Technological Advancements - The AQBioSim platform from SandboxAQ allows for precise simulation and prediction of molecular interactions with GPCRs, enhancing the exploration of chemical space and accelerating drug candidate optimization [4] Company Backgrounds - SandboxAQ is a B2B company focused on AI and quantum techniques, emerging from Alphabet Inc. and backed by leading investors [5] - MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to addressing CNS disorders through circuit-specific pharmacotherapies [6]

Financial Performance - For the nine months ended September 30, 2025, the company reported a net loss of $81.6 million, compared to a net loss of $56.4 million for the same period in 2024, resulting in an accumulated deficit of $281.0 million as of September 30, 2025[105]. - The net loss attributable to common stockholders for the three months ended September 30, 2025, was $29.4 million, compared to a net loss of $19.0 million in 2024, reflecting an increase of $10.4 million[130]. - For the nine months ended September 30, 2025, total operating expenses were $85.7 million, compared to $60.2 million in 2024, an increase of $25.5 million[135]. - Total operating expenses for the three months ended September 30, 2025, increased to $31.5 million from $20.9 million in the same period of 2024, representing a change of $10.6 million[130]. - Interest income for the nine months ended September 30, 2025, was $3.0 million, down from $3.6 million in 2024, a decrease of $0.6 million due to reduced investments[139]. - Cash flows used in operating activities for the nine months ended September 30, 2025, were $91.3 million, compared to $57.3 million in 2024, reflecting an increase of $33.9 million[144]. Revenue Generation - The company has not generated any revenue from product sales to date and does not expect to do so in the foreseeable future[114]. - The company expects to finance operations through public or private equity offerings and debt financings until substantial revenue is generated from product sales[154]. Research and Development - The company expects to incur significant and increasing expenses and net losses as it advances its product candidates through clinical development and seeks regulatory approval[105]. - The company anticipates that research and development expenses will continue to increase substantially as it conducts clinical trials and develops additional product candidates[117]. - The lead product candidate, ML-007C-MA, is currently undergoing two Phase 2 trials, with topline results expected in the second half of 2026 and 2027 for schizophrenia and Alzheimer's disease psychosis, respectively[103]. - The company plans to increase research and development expenses as it continues clinical trial activities and advances preclinical programs, but cannot estimate future costs or timelines for product development[150]. - The company has incurred significant costs related to research and development, including salaries, external development activities, and clinical trial expenses, but cannot accurately predict future costs or timelines for product development[118]. Cash and Investments - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $227.2 million, with an expectation that the estimated net proceeds from the IPO and concurrent private placement will fund operations through 2027[109]. - The company closed its IPO in October 2025, issuing 16,962,500 shares at a price of $17.00 per share, resulting in gross proceeds of $288.4 million and estimated net proceeds of approximately $262.3 million[143]. - Net cash provided by financing activities increased to $197.9 million for the nine months ended September 30, 2025, compared to $118.1 million for the same period in 2024, mainly due to proceeds from the issuance of Series D Preferred Stock[149]. - Net cash used in investing activities decreased to $80.7 million for the nine months ended September 30, 2025, from $113.2 million in the same period of 2024, primarily due to the maturities of short-term investments[148]. Expenses - General and administrative expenses are expected to rise as the company increases personnel to support clinical development and incurs costs associated with being a public company[123]. - General and administrative expenses for the nine months ended September 30, 2025, were $12.0 million, a decrease from $12.4 million in 2024, primarily due to a reduction in professional fees[138]. - Research and development expenses for the three months ended September 30, 2025, were $27.1 million, up from $16.8 million in 2024, an increase of $10.3 million primarily due to an $8.0 million rise in clinical trial expenses[131]. Future Obligations and Risks - The company is subject to potential future payments under grant agreements and licensing agreements contingent upon achieving regulatory and commercial milestones, but cannot estimate the timing or likelihood of these milestones[158][159]. - The company has contractual obligations for lease agreements totaling $7.0 million from January 1, 2025, through the end of the lease term in June 2031[155]. - The company has no outstanding debt as of September 30, 2025, which eliminates interest rate risk related to debt[169]. Economic Factors - Inflation has not had a material effect on the company's consolidated financial statements, although it generally increases labor and clinical trial costs[172]. - The company does not currently engage in currency hedging activities but may consider it in the future to manage foreign currency exposure[171].